Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Understanding Barriers to Diagnosis in a Rare, Genetic Disease: Delays and Errors in Diagnosing Schwannomatosis

View ORCID ProfileVanessa L. Merker, Bronwyn Slobogean, View ORCID ProfileJustin T. Jordan, Shannon Langmead, Mark Meterko, View ORCID ProfileMartin P. Charns, View ORCID ProfileA. Rani Elwy, View ORCID ProfileJaishri O. Blakeley, View ORCID ProfileScott R. Plotkin
doi: https://doi.org/10.1101/2022.01.13.22269170
Vanessa L. Merker
1Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vanessa L. Merker
  • For correspondence: vmerker{at}mgh.harvard.edu
Bronwyn Slobogean
2Department of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin T. Jordan
1Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Justin T. Jordan
Shannon Langmead
2Department of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Meterko
3Analytics and Performance Integration, Office of Quality and Patient Safety, Veterans Health Administration, Bedford, MA
4Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin P. Charns
4Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, MA
5Center for Healthcare Organization and Implementation Research (CHOIR), VA Boston Healthcare System, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin P. Charns
A. Rani Elwy
6Center for Healthcare Organization and Implementation Research (CHOIR), VA Bedford Healthcare System, Bedford, MA
7Department of Psychiatry and Human Behavior, Brown University Warren Alpert Medical School, Providence, RI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Rani Elwy
Jaishri O. Blakeley
2Department of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jaishri O. Blakeley
Scott R. Plotkin
1Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott R. Plotkin
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Diagnosis of rare, genetic diseases is challenging, but conceptual frameworks of the diagnostic process can be used to guide benchmarking and process improvement initiatives. Using the National Academy of Medicine diagnostic framework, we assessed the extent of, and reasons for diagnostic delays and diagnostic errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. We reviewed the medical records of 97 people with confirmed or probable schwannomatosis seen in two U.S. tertiary care clinics. Time-to-event analysis revealed a median time from first symptom to diagnosis of 16.7 years (95% CI, 7.5-26.0 years) and median time from first medical consultation to diagnosis of 9.8 years (95% CI, 3.5-16.2 years). Factors associated with longer times to diagnosis included initial signs/symptoms that were intermittent, non-specific, or occurred at younger ages (p<0.05). Thirty-six percent of patients experienced a misdiagnosis of their underlying genetic condition (18.6%), pain etiology (16.5%) and/or tumor classification (11.3%). One-fifth (19.6%) of patients had a clear missed opportunity for genetics workup that could have led to an earlier schwannomatosis diagnosis. These results suggest that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve diagnosis of schwannomatosis.

Competing Interest Statement

Vanessa Merker reports consulting income from the Neurofibromatosis Network. Justin Jordan reports consulting income from Navio Theragnostics, CereXis, Recursion, Health2047; <1% stock ownership in Navio Theragnostics; Royalties from Elsevier. Jaishri Blakeley has served as a paid consultant for Astella Pharma, Abbvie, TriAct/BiPar Sciences and has had research support from GlaxoSmithKlein, Bristol Meyer Squibb, and AstraZeneca. Scott Plotkin is co-founder of NFlection Therapeutics and NF2 Therapeutics; serves on the Scientific Advisory Board and has stock in SonALAsense; and consults for Akouos.

Funding Statement

This study was funded by Childrens Tumor Foundation Young Investigator Award 2015-01-005 and the Program in Cancer Outcomes Research Training (National Cancer Institute R25CA92203).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Boards at Mass General Brigham, Johns Hopkins Medicine, and Boston University Medical Center gave ethical approval for this work. A waiver of informed consent was granted for this retrospective medical record review.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Grant Numbers: Children’s Tumor Foundation Young Investigator Award 2015-01-005; National Cancer Institute R25CA92203

  • Conflicts of Interest: Vanessa Merker reports consulting income from the Neurofibromatosis Network. Justin Jordan reports consulting income from Navio Theragnostics, CereXis, Recursion, Health2047; <1% stock ownership in Navio Theragnostics; Royalties from Elsevier. Jaishri Blakeley has served as a paid consultant for Astella Pharma, Abbvie, TriAct/BiPar Sciences and has had research support from GlaxoSmithKlein, Bristol Meyer Squibb, and AstraZeneca. Scott Plotkin is co-founder of NFlection Therapeutics and NF2 Therapeutics; serves on the Scientific Advisory Board and has stock in SonALAsense; and consults for Akouos.

  • Minor wording changes throughout manuscript text and inclusion of a revised Figure 2.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 30, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Understanding Barriers to Diagnosis in a Rare, Genetic Disease: Delays and Errors in Diagnosing Schwannomatosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Understanding Barriers to Diagnosis in a Rare, Genetic Disease: Delays and Errors in Diagnosing Schwannomatosis
Vanessa L. Merker, Bronwyn Slobogean, Justin T. Jordan, Shannon Langmead, Mark Meterko, Martin P. Charns, A. Rani Elwy, Jaishri O. Blakeley, Scott R. Plotkin
medRxiv 2022.01.13.22269170; doi: https://doi.org/10.1101/2022.01.13.22269170
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Understanding Barriers to Diagnosis in a Rare, Genetic Disease: Delays and Errors in Diagnosing Schwannomatosis
Vanessa L. Merker, Bronwyn Slobogean, Justin T. Jordan, Shannon Langmead, Mark Meterko, Martin P. Charns, A. Rani Elwy, Jaishri O. Blakeley, Scott R. Plotkin
medRxiv 2022.01.13.22269170; doi: https://doi.org/10.1101/2022.01.13.22269170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)